Literature DB >> 27194138

[IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].

Karoline Pilz1, Christina Jentsch1, Mechthild Krause2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27194138     DOI： 10.1007/s00066-016-0975-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  17 in total

Review 1.  Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group.

Authors:  J M Cosset; M Henry-Amar; J H Meerwaldt
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

2.  Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.

Authors:  Pamela J Schlembach; Richard B Wilder; Dan Jones; Chul S Ha; Luis E Fayad; Anas Younes; Fredrick Hagemeister; Mark Hess; Fernando Cabanillas; James D Cox
Journal:  Cancer J       Date:  2002 Sep-Oct       Impact factor: 3.360

3.  Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.

Authors:  Andrew Wirth; Kally Yuen; Michael Barton; Daniel Roos; Kumar Gogna; Gary Pratt; Craig Macleod; Sean Bydder; Graeme Morgan; David Christie
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

4.  Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.

Authors:  Bradley C Ekstrand; Jennifer B Lucas; Steven M Horwitz; Zhen Fan; Sheila Breslin; Richard T Hoppe; Yasodha Natkunam; Nancy L Bartlett; Sandra J Horning
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

5.  European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.

Authors:  Richard B Wilder; Pamela J Schlembach; Dan Jones; Gregory M Chronowski; Chul S Ha; Anas Younes; Fredrick B Hagemeister; Ibrahim Barista; Fernando Cabanillas; James D Cox
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

6.  Lymphocyte predominance Hodgkin's disease. A clinicopathologic reassessment.

Authors:  M A Trudel; J G Krikorian; R S Neiman
Journal:  Cancer       Date:  1987-01-01       Impact factor: 6.860

7.  Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases.

Authors:  V I Pappa; A J Norton; R K Gupta; A M Wilson; A Z Rohatiner; T A Lister
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

8.  Lymphocyte predominance Hodgkin's disease--an immunohistochemical study.

Authors:  D S Nicholas; S Harris; D H Wright
Journal:  Histopathology       Date:  1990-02       Impact factor: 5.087

9.  Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Authors:  Richard T Hoppe; Ranjana H Advani; Weiyun Z Ai; Richard F Ambinder; Patricia Aoun; Celeste M Bello; Philip J Bierman; Kristie A Blum; Robert Chen; Bouthaina Dabaja; Ysabel Duron; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Ephraim P Hochberg; David G Maloney; David Mansur; Peter M Mauch; Monika Metzger; Joseph O Moore; David Morgan; Craig H Moskowitz; Matthew Poppe; Barbara Pro; Jane N Winter; Joachim Yahalom; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2012-05       Impact factor: 11.908

10.  A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.

Authors:  Eng-Siew Koh; Tu Huan Tran; Mostafa Heydarian; Rainer K Sachs; Richard W Tsang; David J Brenner; Melania Pintilie; Tony Xu; June Chung; Narinder Paul; David C Hodgson
Journal:  Radiat Oncol       Date:  2007-03-15       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.